Caroline Piccand

This study develops L1CAM-CAR T cells that effectively target rhabdomyosarcoma despite low antigen density, showing improved efficacy and safety compared to existing CARs.

This paper evaluates the combination of B7-H3 CAR T cells and ONC206 against DIPG models, showing enhanced anti-tumor efficacy in vitro and in vivo.

This study evaluates CD276 and FGFR4-targeting CAR T cells for rhabdomyosarcoma treatment, showing in vitro efficacy and in vivo tumor clearance, but limited effectiveness in low antigen expression tumors.